Biphenyl-2-yl-carbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)-ethylamino]-nonyl}-piperidin-4-yl ester (THRX-198321) is a single molecule composed of a muscarinic acetylcholine receptor (mAChR) antagonist moiety, represented by the fragment MA, linked by a C9 polymethylene chain to a ␤ 2 -adrenoceptor (␤ 2 AR) agonist moiety, represented by the fragment 8-hydroxy-5-((R)-1-hydroxy-2-methylamino-ethyl)-1H-quinolin-2-one (BA). THRX-198321 exhibited high affinity for mAChR (M 2 pK I,App ϭ 10.57 Ϯ 0.09; M 3 pK I,App ϭ 10.07 Ϯ 0.11) and ␤ 2 AR (pK I,App ϭ 9.54 Ϯ 0.15), with potent mAChR antagonist (M 2 pK I,Fn ϭ 9.69 Ϯ 0.23; M 3 pK I,Fn ϭ 10.05 Ϯ 0.17) and ␤ 2 AR agonist (pEC 50 ϭ 9.25 Ϯ 0.02) activities. Consistent with multivalent interactions, THRX-198321 binding affinity was Ͼ300-fold higher at mAChR and 29-fold higher at ␤ 2 AR relative to its monovalent fragments biphenyl carbamic acid piperidinyl ester (MA) and BA, respectively. THRX-198321 was a competitive antagonist at mAChR (M 2 pK B ϭ 9.98 Ϯ 0.13; M 3 pK B ϭ 10.31 Ϯ 0.89), whereas THRX-198321 agonist activity at ␤ 2 AR was competitively inhibited by propranolol. Interactions of THRX-198321 with an allosteric site on mAChR and a novel extracellular allosteric site on ␤ 2 AR, respectively, were detected by measuring THRX-198321-evoked changes in the dissociation rates for the orthosteric radioligands, [N-methyl-3 H]scopolamine methyl chloride (M 2 pEC 50,diss ϭ 6.73 Ϯ 0.10; M 3 pEC 50,diss ϭ 5.02 Ϯ 0.14) and [4,6-propyl-3 H]dihydroalprenolol (␤ 2 AR pEC 50,diss ϭ 3.82 Ϯ 0.25). The carbostyril-linker fragment (BA-L) binds to the allosteric site of mAChR (M 2 pEC 50,diss ϭ 5.06 Ϯ 0.03; M 3 pEC 50,diss ϭ 4.15 Ϯ 0.25), whereas the MA fragment binds to the allosteric site of ␤ 2 AR (pEC 50,diss ϭ 3.60 Ϯ 0.18). Collectively, these observations suggest that THRX-198321 exhibits a multivalent bimodal orientation in the orthosteric and allosteric binding pockets of mAChR and ␤ 2 AR, a phenomenon that may be unique to this class of molecule.
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality throughout the world and is predicted to become the fourth leading cause of death by 2030 and the third leading cause of chronic disability by 2020 (Mathers and Loncar, 2006) . Bronchodilators, such as mAChR antagonists and ␤ 2 AR agonists, are important treatment options given their ability to improve airflow and reduce the number of exacerbations (Calverley, 2004; Baker et al., 2009) . Several studies have shown that drugs from these classes are effective alone but achieve greater efficacy when administered in combination (Cazzola et al., 2004; Baloira Villar and Vilariñ o Pombo, 2005; van Noord et al., 2005 van Noord et al., , 2006 Aaron et al., 2007; Tashkin et al., 2008) . A single molecule that exhibits both mAChR antagonist and ␤ 2 AR agonist (MABA) activity may offer several advantages over combination therapy of two drug entities. These include a single pharmacokinetic profile, a uniform ratio of activities at the cellular level, and a simplified clinical development program. In addition, the potential exists for combination with an inhaled corticosteroid to offer "triple" therapy in a single inhalation delivery device. We hypothesized that it was possible to discover a molecule exhibiting dual mAChR and ␤ 2 AR pharmacology using a multivalent design strategy (Griffin et al., 2003; Smith et al., 2006; Steinfeld et al., 2007; Long et al., 2008; McKinnell et al., 2009 ). In addition to dual pharmacology, a multivalent ligand is predicted to offer enhanced binding affinity and target specificity relative to its monovalent equivalents (Mammen et al., 1998a,b) . Multivalent binding refers to the interaction of multiple binding motifs on a ligand with adjacent concavities on a single target receptor (intramolecular binding) or on adjacent target receptors (intermolecular binding). Two such adjacent binding pockets on a single target may be an orthosteric binding site and a nearby secondary, or allosteric modulator, site. Allosteric modulators are ligands that bind to sites that are topographically distinct from the primary ligand, or orthosteric, site and may change the conformation of the receptor such that orthosteric ligand affinity and/or efficacy is altered (May et al., 2007) . A novel concept for ligand binding to GPCRs is that of bimodal multivalent binding. Bimodal binding describes the reciprocal modes of binding at two different types of receptor. Thus, for a multivalent ligand composed of structural moieties A and B, at one receptor, A and B bind to orthosteric and allosteric sites, respectively, whereas at the second receptor, A and B bind to allosteric and orthosteric sites, respectively.
For a multivalent ligand to bind in a bimodal manner at two distinct receptors, the respective receptors should, ideally, each contain at least two binding pockets that are similar enough to accommodate the same ligand binding motifs and have a similar spatial relationship on each receptor. In addition to the ACh orthosteric binding site, mAChRs exhibit at least one nearby, yet topographically distinct, well characterized allosteric modulator site that binds mAChR allosteric ligands, such as gallamine, W84, and obidoxime (Tränkle and Mohr, 1997) . We have demonstrated previously that 4-{N-[7-(3-(S)-(1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(n-propyl)amino}-1-(2,6-dimethoxybenzyl)piperidine (THRX-160209), a compound that exhibits simultaneous binding interactions at the orthosteric and "gallamine" allosteric sites of M 2 mAChR, is a high-affinity multivalent ligand with selectivity over all other mAChRs (Steinfeld et al., 2007) .
Although norepinephrine may occupy a comparable orthosteric site on ␤ 2 AR, no known extracellular allosteric modulators sites have been described, to the best of our knowledge. A salmeterol "exosite" has been described and located on ␤ 2 AR; however, the interaction between the salmeterol aromatic ring and this site enhances receptor residency time and not affinity or potency (Green et al., 1996) . Furthermore, no allosteric modulatory effects have been reported for this site. An intracellular Zn 2ϩ binding site has been described for ␤ 2 AR (Swaminath et al., 2002 (Swaminath et al., , 2003 , but this site is inaccessible to large, cell-impermeant ligands. Extracellular secondary sites or allosteric binding pockets may exist on ␤ 2 AR but these may have avoided detection because of tolerance of binding (i.e., allosteric ligand binding failing to modulate orthosteric ligand binding) or because modulatory effects are too modest to measure.
In the present study, we describe the pharmacological profile of a novel multivalent ligand that exhibits dual mAChR antagonist and ␤ 2 AR agonist pharmacologies (MABA). Biphenyl-2-yl-carbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinolin-5-yl)-ethylamino]-nonyl}-piperidin-4-yl ester (THRX-198321) (Fig. 1) is a representative MABA that was the product of a multivalent design strategy targeting the orthosteric and allosteric sites on mAChR, the orthosteric site on ␤ 2 AR and a novel allosteric site on ␤ 2 AR, and was chosen as a tool for the present study. We provide evidence to suggest that the binding orientations for THRX-198321 at mAChR and ␤ 2 AR are bimodal. 
Materials and Methods

Materials
, and 8-hydroxy-5-((R)-1-hydroxy-2-nonylamino-ethyl)-1H-quinolin-2-one (BA-L), and various linker analogs of THRX-198321 (C7-C12) were prepared at Theravance. HTRF cAMP and IP-One assay kits were purchased from CisBio International (Bagnols sur Cè ze, France).
Cell Culture and Membrane Preparation. Cells were grown under 5% CO 2 at 37°C. Chinese hamster ovary (CHO)-K1 cells stably transfected with the human recombinant M 2 or M 3 mAChR were grown in Ham's F12 medium containing 10% fetal bovine serum and 250 g/ml G-418 (Geneticin). Human embryonic kidney (HEK)-293 cells transfected with human recombinant ␤ 2 AR were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 250 g/ml G-418. Cells were grown to confluence and harvested with phosphate-buffered saline (PBS) containing 5 mM EDTA. For intact cell assays, lifted cells were washed with PBS and used immediately. For membrane preparations, cells were suspended in ice-cold 10 mM HEPES with 10 mM EDTA, pH 7.4 (mAChR CHO-K1 cells) or ice-cold 75 mM Tris with 10 mM EDTA, pH 7.4 (␤ 2 AR HEK-293 cells) and homogenized using a cell disrupter. The homogenate was sedimented by centrifugation (500g, 10 min). The supernatant was then centrifuged again (40,000g, 20 min) , and the pellets were suspended in 10 mM HEPES buffer with 20 mM NaCl, pH 7.4 (mAChR CHO-K1 cell membranes) or 75 mM Tris buffer, pH 7.4 (␤ 2 AR HEK-293 cell membranes) and stored at Ϫ80°C. These preparations typically yielded 2.4, 2.7, or 2.5 pmol/mg protein of ␤ 2 AR, M 2 , or M 3 receptors, respectively, as determined using cAMP Accumulation Assay. To determine ␤ 2 AR agonist potencies, cAMP accumulation in HEK-293 cells expressing ␤ 2 AR was measured in white half-area 96-well microplates using the HTRF cAMP Dynamic kit (CisBio International). In brief, cells were stimulated for 15 min at 37°C with test compounds in PBS with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. Inhibition of the agonist response was measured in the presence of the ␤ 2 AR antagonist propranolol. The reaction was stopped with the addition of vendor-supplied lysis/conjugation buffer containing HTRF assay reagents: the d2-labeled cAMP, followed by the europium cryptatelabeled anti-cAMP antibody. The assay was incubated overnight at 20°C, and time-resolved fluorescence resonance energy transfer signals were measured 60 s after excitation at 317 nm and emission at 585 and 665 nm using a Safire 2 instrument (Tecan Group Ltd, Mä nnedorf, Switzerland). Ratios of relative fluorescence units (RFU) measured at each wavelength (10 4 ϫ RFU 665 nm /RFU 585 nm ) were plotted against concentration of test compound and analyzed by nonlinear regression using a four-parameter logistic function in Prism 5.0 (GraphPad Software, San Diego, CA) to determine agonist EC 50 values.
Myoinositol-1-Phosphate Accumulation Assay. To determine M 3 receptor antagonist potencies, myoinositol-1-phosphate (IP 1 ) accumulation in CHO-K1 cells expressing M 3 mAChR was measured in 96-well microplates using the HTRF IP-One terbium assay kit (CisBio International). In brief, cells were stimulated for 2 h at 37°C with the mAChR agonist oxotremorine in the presence or absence of test ligands by using the vendor-supplied stimulation buffer. The reaction was stopped by the addition of vendorsupplied lysis/conjugation buffer containing HTRF assay reagents: the d2-labeled IP 1 , followed by the terbium cryptatelabeled anti-IP 1 antibody. The assay was incubated overnight at 20°C, and time-resolved fluorescence resonance energy transfer signals were measured as described above. Data were analyzed by nonlinear regression using a four-parameter logistic function in Prism 5.0 to determine antagonist IC 50 values. Slope factors were not different from unity, and therefore, antagonist pK I,Fn values were calculated from IC 50 values, (Cheng and Prusoff, 1973) using the oxotremorine EC 50 and concentration.
[ 35 S]GTP␥S Binding Assay. To determine M 2 antagonist potencies, inhibition of oxotremorine-stimulated [
35 S]GTP␥S binding to CHO-K1 cell membrane fractions expressing M 2 mAChR was measured. Test compound and 0.5 M oxotremorine were incubated together with membranes for 1 h in assay buffer consisting of 10 mM HEPES with 20 mM NaCl and 0.025% BSA, pH 7.4, at 20°C. A second 1-h incubation period followed the addition of 3 M GDP and 0.4 nM [
35 S]GTP␥S. Membranes were then collected on 0.1% BSA pretreated GF/B filter plates (PerkinElmer Life and Analytical Sciences, Waltham, MA) via rapid filtration. Bound radioligand was measured by scintillation counting and cpm data were analyzed using a four-parameter logistic equation using Prism 5.0. The slopes of oxotremorine response curves were not equal to unity; therefore, antagonist inhibition constants (K I,Fn ) values were calculated from IC 50 values using the equation
where [A] is the oxotremorine concentration and n is the slope factor (Leff and Dougall, 1993) . Dissociation Kinetics Assays. mAChR ligand dissociation assays were performed as described previously (Steinfeld et al., 2007) . Membrane fractions expressing mAChR or ␤ 2 AR were labeled with 0.5 nM [ 3 H]NMS or 0.5 nM [ 3 H]DHA, respectively, for 1 h at 20°C in 10 mM HEPES, 20 mM NaCl, or 75 mM Tris buffer. In addition, some studies were conducted using intact HEK-293 cells expressing ␤ 2 AR in an isotonic buffer consisting of 75 mM Tris and 3.5% D-mannitol supplemented with 1% BSA or 1 mM EDTA. In these studies, cell integrity was confirmed before and after each experiment by trypan blue staining. After equilibrium with the radioligand was established, 10 M atropine (mAChR) or 10 M propranolol (␤ 2 AR) was added at various time points to prevent reassociation of the radioligand with the receptor. Additions were made in the presence or absence of test compound and, in the case of M 2 mAChR, with or without obidoxime. Membrane preparations or cells were collected onto 0.3% polyethylenimine-treated GF/B filter plates and radioactivity was measured by scintillation counting. Data (cpm) were normalized to percentage of total specific binding and analyzed using the monoexponential decay function in Prism 5.0 to derive the apparent dissociation rate constants in the presence of each concentration of allosteric modulator (k obs ). The apparent rate constant was then expressed as a percentage of the apparent rate constant for the radioligand determined in the absence of allosteric modulator (k off ). The data (k obs /k off , percentage) were then plotted versus ligand concentration and analyzed by nonlinear regression to calculate allosteric modulator pEC 50,diss values or the negative log of the concentration required to retard the orthosteric radioligand dissociation rate by 50%.
Inhibition Radioligand Binding Assay. Inhibition radioligand binding assays were conducted with 0.5 nM [
3 H]NMS in a 10 mM HEPES buffer containing 20 mM NaCl and 0.025% BSA, pH 7.4, at 20°C (mAChR) or with 0.5 nM [
3 H]DHA in a 75 mM Tris buffer containing 0.025% BSA, pH 7.4, at 20°C (␤ 2 AR). Nonspecific binding was defined in the presence of 10 M atropine or 10 M propranolol (mAChR or ␤ 2 AR, respectively). Membrane fractions were incubated with radioligand and unlabeled test compounds for 2 h at 20°C. After separation by vacuum filtration onto GF/B filter plates presoaked with polyethylenimine, the quantity of membrane-bound radioligand was measured by scintillation counting. Data (cpm) were normalized to percentage specific binding and analyzed using a four-parameter logistic equation in Prism 5.0. Hill coefficients did not differ significantly from unity; therefore, IC 50 values were determined with slopes fixed to unity. Apparent K I values (K I,App ) were calculated from the IC 50 values (Cheng and Prusoff, 1973) .
Competitive Interactions Analyses. Antagonist-induced rightward shifts of concentration-response curves were analyzed by nonlinear regression (Lew and Angus, 1995) to check for competitive interactions and calculate pK B or pA 2 values for the antagonist. Data were also plotted according to the method of Arunlakshana and Schild (1959) for visualization.
Statistics. Data are presented as mean Ϯ S.D., unless otherwise noted. For antagonist regression analyses, values are reported as pK B or pA 2 Ϯ S.D. When checking for a competitive interaction between agonist and antagonists, fits to the various nonlinear regression models were compared using an F test. The statistical MABA Binding Interactions at mAChR and ␤ 2 AR 391 at ASPET Journals on October 29, 2017 molpharm.aspetjournals.org significance of differences between values was determined using a student's t test. Differences were considered to be statistically significant for p Ͻ 0.05.
Results
MABA Potencies and Orthosteric Site Interactions
Measured by Functional In Vitro Assays. In HTRF inositol phosphate studies designed to measure functional antagonist activity in cells expressing M 3 mAChR, THRX-198321 inhibited oxotremorine-stimulated turnover of inositol phosphates in a concentration-dependent manner (pK I,Fn ϭ 10.05 Ϯ 0.17). Furthermore, increasing concentrations of THRX-198321 or the MA fragment shifted oxotremorine concentration-response curves to the right in a parallel fashion. Curve shifts were analyzed by nonlinear regression models (Lew and Angus, 1995) in which oxotremorine pEC 50 values were plotted against the concentrations of the antagonist (Fig. 2, A and B) . Data for THRX-198321, MA, and atropine were best fit to the model that is analogous to a linear Schild plot with a slope of unity. These data suggest a competitive interaction between oxotremorine and THRX-198321, MA and atropine. pK B values of 10.31 Ϯ 0.89, 7.05 Ϯ 0.52, and 8.58 Ϯ 0.26 were calculated for THRX-198321, MA, and atropine, respectively (Table 1) . To more easily visualize the data, curves shifts are represented as Schild plots (Fig. 2, C THRX-198321 increased cAMP accumulation in HEK-293 cells expressing ␤ 2 AR in a concentration-dependent manner (pEC 50 ϭ 9.25 Ϯ 0.02). Likewise, we observed agonist activity for the THRX-198321 fragment, BA (pEC 50 ϭ 8.66 Ϯ 0.12). THRX-198321 and BA evoked full agonist responses, with intrinsic activities of 0.93 Ϯ 0.17 and 0.90 Ϯ 0.20, respectively, relative to isoproterenol. The activities of both agonists were inhibited by the ␤ 2 AR antagonist, propranolol. Increasing concentrations of propranolol resulted in parallel rightward shifts of THRX-198321, BA, and isoproterenol concentration-response curves. Nonlinear regression analysis of the resulting curve shifts revealed that the data for THRX-198321 best fit to the model analogous to a linear Schild plot with a slope equal to unity (propranolol pK B ϭ 8.41 Ϯ 0.11; Fig. 3 ). For BA and isoproterenol, the curve-shift data fit best the model analogous to a linear Schild plot with a slope not equal to unity (BA propranolol pA 2 ϭ 8.63 Ϯ 0.24, slope ϭ 1.21 Ϯ 0.08; isoproterenol propranolol pA 2 ϭ 8.67 Ϯ 0.27, slope ϭ 1.21 Ϯ 0.10). Propranolol antagonist potencies (pA 2 or pK B ) were similar for each agonist and were within the range of potencies and binding affinities (8.3-9.0) reported by other groups (Arch et al., 1984; Smith and Teitler, 1999) . Overall, these data indicate that the antagonist propranolol competitively inhibited the agonists THRX-198321, BA, and isoproterenol. Furthermore, these data suggest that THRX-198321 binds to site on ␤ 2 AR coincident with isoproterenol and propranolol via the BA binding moiety.
Allosteric Interactions Measured by Orthosteric Radioligand Dissociation Assays. Kinetic assays using excess competing orthosteric ligand were employed to study potential interactions of THRX-198321, or Table 2 ). Dissociation curves were monophasic in the pres- Fig. 3 . Inhibition of agonist-stimulated ␤ 2 AR activity. A, agonist-stimulated cAMP accumulation in HEK-293 cells stably transfected with ␤ 2 AR was inhibited by propranolol. Propranolol-induced rightward shifts of agonist stimulated cAMP accumulation were analyzed using nonlinear regression (Lew and Angus, 1995) . B, for visualization, curve shifts were expressed as dose ratios (DR) in the form of a Schild plot. ␤ 2 AR agonists THRX-198321 (F), BA (), or isoproterenol (E) were tested in three separate experiments performed in duplicate. ence of all compounds studied (Fig. 4) . (Fig. 5) . A pA 2 value of 4.04 Ϯ 0.73 was calculated for obidoxime, which is comparable with the value measured when tested with W84 in similar studies (Ellis and Seidenberg, 1992 ; Trä nkle and Mohr, 1997; Steinfeld et al., 2007) . The data fit best to the Lew and Angus model that describes a linear Schild plot with a slope factor less than 1 (slope ϭ 0.73 Ϯ 0.07). These data suggest that THRX-198321 binds to an allosteric site that overlaps with the common allosteric binding site defined by typical allosteric modulators such as gallamine and W84, that there is a degree of negative cooperativity between obidoxime and THRX-198321 or that data may be a composite of both activities. In other words, the orthosteric moiety of THRX-198321 may negatively modulate obidoxime binding at the allosteric site, yet the allosteric moiety occupies the "gallamine" allosteric site competitively.
The effects of THRX-198321 or MA on [ 3 H]DHA dissociation rates at ␤ 2 AR were also investigated. In studies using intact HEK-293 cells expressing ␤ 2 AR, high concentrations (Ն100 M) of THRX-198321 or MA were required to slow the dissociation of [ 3 H]DHA from the control rate (t 1/2 ϭ 32 Ϯ 9 min, k off ϭ 0.022 Ϯ 0.007 min Ϫ1 ). These data were generated using an EDTA buffer to inhibit cell aggregation. At the highest tested THRX-198321 concentration (1 mM), the k obs was reduced to 0.0078 Ϯ 0.0016 min Ϫ1 . The intrinsic solubility of THRX-198321 in this buffer system prevented testing at higher concentrations. The pEC 50,diss values for THRX-198321 and MA were 3.82 Ϯ 0.25 and 3.60 Ϯ 0.27, respectively. The shape of the concentration response curves fit to a 4-parameter model in which the curve bottoms did not reach full inhibition of [ 3 H]DHA rate retardation (maximum inhibition Ϸ 70%). These data are consistent with allosteric ligands interactions that are analogous to a partial agonist. A more modest effect was observed in similar studies using 1% BSA buffer to inhibit cell aggregation, where the [ MABA ligand can form a ternary complex with the radioligand and ␤ 2 AR before [ 3 H]DHA dissociation, supporting the claim that these ligands bind to an allosteric modulator site on ␤ 2 AR and that the allosteric site is extracellular (Fig. 6 ). In contrast, 1 mM BA had no effect on [ Cheng-Prusoff (1973) , as summarized in Table 3 . THRX-198321 bound tightly to M 2 and M 3 mAChR, with a modest degree of selectivity (3-fold) for M 2 receptors over M 3 receptors (M 2 pK I,App ϭ 10.57 Ϯ 0.09; M 3 pK I,App ϭ 10.07 Ϯ 0.11; p Ͻ 0.001). In general, THRX-198321 binding affinities were similar across the five muscarinic receptors. [THRX-198321 binding affinities (pK I,App ) measured using CHO-K1 cell membranes expressing human recombinant M 1 , M 4 , or M 5 receptors were determined to be 9.65 Ϯ 0.20, 9.83 Ϯ 0.08, or 9.00 Ϯ 0.07, respectively.] At ␤ 2 AR, THRX-198321 also exhibited high affinity (Table 3) . In contrast to the selectivity profile observed at muscarinic receptors, THRX-198321 was selective for ␤ 2 AR over ␤ 1 AR. [THRX-198321 binding affinity (pK I,App ) measured using HEK-293 cell membranes expressing human recombinant ␤ 1 -adrenoceptors was determined to be 7.12 Ϯ 0.10].
To explore the multivalent properties of THRX-198321, the various truncated analogs were tested alone and in combination in the M 2 and M 3 mAChR and the ␤ 2 AR radioligand binding assays. MA exhibited higher affinity for M 2 and M 3 mAChR than ␤ 2 AR (M 2 pK I,App ϭ 7.33 Ϯ 0.20; M 3 pK I,App ϭ 7.51 Ϯ 0.12; ␤ 2 AR pK I,App ϭ 4.94 Ϯ 0.11), whereas BA demonstrated higher affinity for ␤ 2 AR than M 2 and M 3 mAChR (M 2 pK I,App ϭ 5.07 Ϯ 0.07; M 3 pK I,App ϭ 4.50 Ϯ 0.09; ␤ 2 AR pK I,App ϭ 8.08 Ϯ 0.08). For the linker-conjugated fragments MA-L and BA-L, pK I,App values were indistinguishable or similar to pK I,App values for the unconjugated fragments, except that for MA and MA-L at M 2 , a difference in apparent affinity of approximately 10-fold was observed.
When the corresponding linker conjugated and unconjugated fragments (i.e., MA ϩ BA-L or BA ϩ MA-L) were coincubated, inhibition binding curve shapes did not deviate from one-site logistic models. Therefore, data were again analyzed assuming competitive inhibition of [ 3 H]NMS. The apparent affinity measurement for any pair of fragments did not differ significantly from the pK I,App value measured for the higher affinity frag- ]NMS dissociation rate retardation at human M 2 receptors were rightward shifted in the presence of 10 mM (F), 5.6 mM (f), 3.2 mM (OE), 1.8 mM (), 1 mM (ࡗ), 560 M (Ⅺ), 320 M (Ⅺ), 180 M (‚), and 100 M (ƒ) obidoxime, relative to concentration-effect curves measured in the absence of obidoxime (᭛). Analyses of obidoxime-induced shifts in concentration-effect curves for THRX-198321 were performed using nonlinear regression (Lew and Angus, 1995) (C), and plotted against log concentration of obidoxime as a Schild regression (D) for visualization. Dose ratios were calculated by dividing the EC 50,diss determined in the presence of obidoxime by the EC 50,diss determined in the absence of obidoxime.
MABA Binding Interactions at mAChR and ␤ 2 AR 395
at ASPET Journals on October 29, 2017 molpharm.aspetjournals.org ment when assayed alone (Table 3) . These data provide evidence for the multivalent mechanism of binding for THRX-198321, demonstrating that these pharmacophores must be linked to achieve subnanomolar activities.
To further explore the binding interaction of the carbamic acid moiety at the putative secondary site on ␤ 2 AR, a urea analog of THRX-198321 was synthesized and tested in the radioligand binding assays. The change of an oxygen in the carbamate moiety of THRX-198321 to a nitrogen in the urea analog (Fig. 7) resulted in apparent binding affinities that were 21-, 39-, and 62-fold weaker than THRX-198321 at M 2 , M 3 , and ␤ 2 , respectively (Table 4) .
Analogs of THRX-198321 with varying linker lengths (C7-C12; Fig. 7 ) were synthesized and tested in the radioligand binding assays to explore the distances between orthosteric and allosteric sites located on ␤ 2 AR and mAChR, respectively. It is noteworthy that the C9 polymethylene linker in THRX-198321 was the optimal linker length for mAChRs and ␤ 2 AR (Fig. 8) . For each linker analog, the rank order of affinities was M 2 mAChR Ͼ M 3 mAChR Ͼ ␤ 2 AR. The rank order of affinities at M 2 and M 3 mAChR was THRX-198321 Ͼ C10 Ͼ C8 Ͼ C11 Ͼ C7 Ͼ C12, whereas the rank order of affinities at ␤ 2 AR was THRX-198321 Ͼ C7 ϭ C8 ϭ C10 Ͼ C11 Ͼ C12 (Table 4) .
Ligand binding free energies were calculated from apparent inhibition binding constants using the equation, ⌬G ϭ Fig. 6 . Concentration-dependent effects of allosteric ligands on observed dissociation rates of [ ϪR ⅐ T ln(K I,App ),where R is the gas constant (1.98 ϫ 10
and T is temperature (310 K). For THRX-198321, free energy values were calculated to be 14.9, 14.2, and 13.5 kcal/mol for M 2 , M 3 mAChR, and ␤ 2 AR, respectively. These values are summarized in Table 5 . Sums of individual values for fragment pairs are also reported for comparison. For the pair of THRX-198321 fragments lacking the linker extension (MA and BA), the sums of free energies were calculated to be 17.5, 17.0, and 18.4 kcal/mol for M 2 , M 3 mAChR, and ␤ 2 AR, respectively. The binding energy for the urea analog of THRX-198321 was 11.0 kcal/mol, a decrease in binding energy of 2.5 kcal/mol relative that for THRX-198321 at ␤ 2 AR.
Discussion
In the present study, we have described the pharmacological profile of a novel, potent dual pharmacology ligand, THRX-198321, discovered using a multivalent design strategy. THRX-198321 was chosen as a tool for the present study as a representative MABA exhibiting muscarinic receptor antagonist and beta adrenoceptor agonist properties. The pharmacological activities and binding modes of THRX-198321 were examined at M 2 mAChR, M 3 mAChR, and ␤ 2 AR, receptors, which are relevant to smooth muscle contraction and modulation of bronchodilation.
The design of multivalent ligands for GPCRs has been described previously (Disingrini et al., 2006; Steinfeld et al., 2007; Valant et al., 2008; Antony et al., 2009; Kebig et al., 2009) ; however, here concepts in multivalency were extended to introduce dual pharmacology, an atypical characteristic of multivalent ligands. The dual pharmacological activity of THRX-198321 is attributed to structural elements found within the ligand. The BA moiety contains a carbostyril core, a well characterized ␤ 2 AR agonist pharmacophore (Yoshizaki et al., 1976; Milecki et al., 1987) . The biphenyl carbamic acid moiety, represented by MA, is of a class of compounds that has been reported as mAChR antagonists (Naito et al., 1998a,b) . Truncated THRX-198321 fragments retained their respective pharmacological activities as confirmed using assays designed to measure functional agonism or antagonism. Covalent linkage of these fragments by a C9 polymethylene chain resulted in a single molecule exhibiting potent mAChR antagonist and ␤ 2 AR agonist activities.
THRX-198321 exhibits three characteristics of binding interactions that are consistent with multivalent interactions: 1) multiple binding interactions at a given receptor, 2) enhanced binding affinity for the multivalent ligand relative to monovalent fragments, and 3) a quantifiable multivalent effect. These are discussed in further detail in the sections that follow.
THRX-198321 and the MA moiety were competitive with the mAChR agonist oxotremorine, providing evidence that the MA moiety of THRX-198321 binds to the mAChR orthosteric site. Kinetic data (retardation of [ 3 H]NMS dissociation rates) provide evidence that THRX-198321 can cobind to the mAChR when occupied by the orthosteric radioligand, suggesting that THRX-198321 binds to a mAChR allosteric site. The specificity of this allosteric interaction at M 2 was confirmed using the allosteric modulator inhibitor obidoxime, which also provided evidence that THRX-198321 binds to a region on M 2 receptors coincident with other typical allosteric modulators, such as gallamine and W84 (Ellis and Seidenberg, 1992; Trä nkle and Mohr, 1997; Steinfeld et al., 2007) . A similar study showing the interaction between obidoxime and the mAChR allosteric moiety of THRX-198321, BA, could not be performed because the potency of BA in this assay was too weak. Formation of a ternary complex of [ 3 H]NMS, THRX-198321 (or BA), and M 3 mAChR also was observed; Before this report, the only known allosteric modulator for the ␤ 2 AR was Zn 2ϩ , the binding site for which seems to be located on the third cytoplasmic loop of the receptor (Swaminath et al., 2003) . Here we report the first evidence for an allosteric interaction at ␤ 2 AR using a small synthetic ligand, the binding site for which seems to be extracellular. THRX-198321 and MA slowed the dissociation rate of [ 3 H]DHA from ␤ 2 AR in a manner consistent with an allosteric interaction. That these studies were performed using intact cells suggests that the allosteric site that binds THRX-198321 and MA is extracellular and thus distinct from the Zn 2ϩ allosteric binding site previously reported. The potency of MA is consistent with binding energies sufficient to increase binding affinity of BA in a multivalent capacity. These data are consistent with the hypothesis that the MA moiety of THRX-198321 binds to a novel allosteric site on ␤ 2 AR, the location of which remains to be identified.
The ␤ 2 AR agonist activities of THRX-198321 and, more specifically, BA, are competitively inhibited by propranolol, supporting our hypothesis that the carbostyril moiety of THRX-198321 binds to the ␤ 2 AR orthosteric site. These data, taken together with the kinetic data, support the hypothesis that THRX-198321 binds to distinct orthosteric and allosteric sites on ␤ 2 AR in a multivalent manner.
We demonstrated enhanced binding affinity for the multivalent ligand, THRX-198321, relative to monovalent fragments at mAChR. That mAChR binding affinities are increased approximately 2 orders of magnitude when MA is covalently linked to BA, to form THRX-198321, supports the hypothesis that THRX-198321 is a multivalent ligand. This conclusion is corroborated by observed increases in functional antagonist potencies for THRX-198321 relative to THRX-198321 fragments. Radioligand binding data for the linker-conjugated fragments suggest that the linker may play a significant role in receptor binding. However, as discussed previously (Steinfeld et al., 2007) , the gains in mAChR binding affinity for the linker conjugated fragments (e.g., MA-L relative to MA) are believed to represent overestimates of the linker contribution to enhancement of the receptor binding affinity.
Increases in binding affinity for the multivalent ligand relative to the monovalent fragments were also observed at ␤ 2 AR; however, these were more modest than observed at mAChRs. These data suggest that although there is positive cooperativity between MA and BA fragments at both mAChR and ␤ 2 AR, the cooperativity is greater in magnitude at M 2 and M 3 mAChR than at ␤ 2 AR.
To quantify the multivalent effect for THRX-198321, binding free energies were calculated from apparent binding affinities. The sum of free energies for THRX-198321 fragments represents the upper bound of the free energy of binding of THRX-198321, assuming the maximum possible multivalent effect. However, several important factors prohibit a quantitative assessment here. First, because the mode of binding for the linker-conjugated fragments may not exactly mimic the mode of binding for the MABA, the reported binding data may overestimate the contribution of the linkerconjugated fragment. Conversely, the linker may contribute to the binding energy through direct contact with the receptor. Second, the sum of the free energies of the fragments measured independently does not account for interaction terms (cooperativity, either positive or negative). Furthermore, cooperativities between allosteric fragments and orthosteric radioligands may not accurately represent cooperativities between allosteric and orthosteric fragments of THRX-198321. In addition to providing information regarding the multivalent nature of THRX-198321, binding free-energy data may also quantify the importance of binding to a given binding pocket. At ␤ 2 AR, the apparent binding affinities for BA and the urea analog of THRX-198321 were similar, suggesting that the binding energy for the urea analog at ␤ 2 AR is derived largely, if not entirely, from the BA moiety. The 2.5 kcal/mol gain in binding energy for THRX-198321 relative to the urea analog at ␤ 2 AR represents a significant gain in binding energy that is consistent with the idea that the carbamic acid moiety of THRX-198321 occupies a secondary site on ␤ 2 AR. It is noteworthy that structural differences between the carbamic acid and urea are minor, suggesting that binding at the ␤ 2 AR allosteric site is highly sensitive to small structural changes.
The data presented here are consistent with the notion that THRX-198321 binds in a multivalent manner at both mAChR and ␤ 2 AR and that the orientation of THRX-198321 relative to orthosteric and allosteric sites is bimodal (Fig. 9) . By extension, it should be possible to define distinct structure-activity relationships at both the orthosteric and allosteric binding pockets on mAChR and ␤ 2 AR that bind THRX-198321. To the best of our knowledge, the phenomenon of bimodal binding at GPCRs is unprecedented.
It is interesting to speculate as to why it might be possible for a MABA to bind in the modes described. A more specific inquiry might be made to understand why a ␤ 2 AR agonist serves as a binding anchor at an allosteric site on mAChRs for THRX-198321. Receptor "specific" ligands can be integrated into a multivalent ligand almost interchangeably, which suggests that there are similarities to be considered, at least within these specific binding regions. Moreover, the spatial relationship between the orthosteric and allosteric Fig. 9 . Cartoon depicting the multivalent modes of binding for THRX-198321 at mAChR (M) and ␤ 2 AR. Our data suggest that THRX-198321 exhibits bimodal binding at these receptors, where the mAChR orthosteric moiety MA binds to a novel allosteric site on ␤ 2 AR. Likewise, the ␤ 2 AR orthosteric moiety BA binds to the mAChR allosteric site coincident with other typical mAChR allosteric modulators, such as W84. sites on these receptors seems to be similar. It is possible that mAChR and ␤ 2 AR are more similar than previously thought. This is little more than speculation in the absence of mutagenesis data showing the location of the ␤ 2 AR allosteric site and comparisons with sites identified on mAChR. However, our data may begin to shed light on what may be evolutionary relationships between these receptors. Many questions remain unanswered, but it is hoped that this work will stimulate further studies and debate.
From a therapeutic perspective, our discovery of MABA ligands was the combined result of successes in multivalent drug design and respiratory disease research that represents a potential major breakthrough in novel therapies for COPD. A single molecule exhibiting dual pharmacological activities represents a novel approach toward the discovery of bronchodilators. Several MABAs are currently being clinically evaluated, the most advanced being GSK961081 (TD-5959). The combined activities of a MABA may result in synergistic increases in bronchodilation and therefore offer the potential for superior efficacy relative to therapies with a single activity and may make triple therapy with a corticosteroid, for example, more feasible.
